How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

287 results for

Baclofen Withdrawal

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Baclofen for alcohol withdrawal. Full Text available with Trip Pro

Baclofen for alcohol withdrawal. Baclofen shows potential for rapidly reducing symptoms of severe alcohol withdrawal syndrome (AWS) in people with alcoholism. Treatment with baclofen is easy to manage and rarely produces euphoria or other pleasant effects, or craving for the drug. This is an updated version of the original Cochrane Review published in 2015, Issue 4.To assess the efficacy and safety of baclofen for people with AWS.We updated our searches of the following databases to March 2017 (...) with AWS. We excluded uncontrolled, non-randomised, or quasi-randomised trials. We included both parallel group and cross-over studies.We used standard methodological procedures expected by Cochrane.We included three RCTs with 141 randomised participants. We did not perform meta-analyses due to the different control interventions. For the comparison of baclofen and placebo (1 study, 31 participants), there was no significant difference in Clinical Institute Withdrawal Assessment of Alcohol Scale

2017 Cochrane

2. Baclofen for alcohol withdrawal. (Abstract)

Baclofen for alcohol withdrawal. The treatment baclofen shows potential for rapidly reducing symptoms of severe alcohol withdrawal syndrome (AWS) in people with alcoholism. Treatment with baclofen is easy to manage and rarely produces euphoria or other pleasant effects, or craving for the drug. This is an updated version of the original Cochrane review published in Issue 2, 2013.To assess the efficacy and safety of baclofen for people with AWS.We searched the Cochrane Drugs and Alcohol Group (...) by an independent party. We contacted study authors for additional information where needed. We collected adverse effects information from the trials.Two RCTs with a total of 81 participants were eligible according to the inclusion criteria. One study suggested that both baclofen and diazepam significantly decreased the Clinical Institute Withdrawal Assessment of Alcohol Scale, Revised (CIWA-Ar) score, without any significant difference between the two interventions. The other study showed no significant

2015 Cochrane

3. Baclofen for alcohol withdrawal. (Abstract)

Baclofen for alcohol withdrawal. The treatment baclofen can rapidly reduce symptoms of severe alcohol withdrawal syndrome (AWS) in alcoholic patients, with a significant reduction in the cost. Baclofen is easy to manage, and rare euphoria, craving and other pleasant effects are reported by patients treated with baclofen.To assess the efficacy and safety of baclofen for patients with AWS.We searched the Cochrane Central Register of Controlled Trials (CENTRAL) in The Cochrane Library (October (...) the trials.We identified a total of 113 references from all electronic databases searched excluding duplicates. After screening of titles and abstracts, full papers of 10 studies were obtained and assessed for eligibility. Finally, two RCTs with 81 participants were eligible according to the inclusion criteria. Regarding the efficacy, one study suggested that both baclofen and diazepam significantly decreased the Clinical Institute Withdrawal Assessment of Alcohol Scale Revised (CIWA-Ar) score, without any

2013 Cochrane

4. Comparative efficacy of baclofen and lorazepam in the treatment of alcohol withdrawal syndrome. (Abstract)

Comparative efficacy of baclofen and lorazepam in the treatment of alcohol withdrawal syndrome. Benzodiazepines (BDZs) have been the treatment of choice for alcohol withdrawal syndrome (AWS); however, they are associated with several side effects and also have abuse potential. In some studies, the use of baclofen has been effective in reducing symptoms of alcohol withdrawal symptoms.The objective of this study was to compare the efficacy of baclofen and benzodiazepine (lorazepam) in reducing (...) symptoms of AWS.It was a single-center, randomized, open-label study. Patients with alcohol dependence syndrome were enrolled in the study and randomized into two groups using computer-generated random table number. Baclofen (experimental group, 10 mg three times a day) and BZDs (control group, lorazepam, 8-12 mg/day in divided doses) were orally administered for reducing symptoms of alcohol withdrawal. Both groups received Vitamin B1 (100 mg/day through intramuscular route) and psychotherapeutic

2019 Indian journal of psychiatry Controlled trial quality: uncertain

5. Subcutaneous dexmedetomidine for baclofen withdrawal during palliative sedation. (Abstract)

Subcutaneous dexmedetomidine for baclofen withdrawal during palliative sedation. Sudden cessation of baclofen can produce a withdrawal syndrome even if it was previously orally administered. We present the case of a man who exhibited signs of baclofen withdrawal syndrome during palliative sedation. Attempts were made to induce muscle relaxation with ever-increasing doses of benzodiazepine. Ultimately, control over the withdrawal syndrome was regained by using a continuous subcutaneous infusion (...) (CSCI) of dexmedetomidine, a highly selective α2 adrenergic agonist. Very limited published reports concerning CSCI of dexmedetomidine exist. To our knowledge, this is the first case to report its use as an adjunctive agent to treat baclofen withdrawal syndrome through the subcutaneous route in the palliative care setting.© Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.

2019 BMJ Supportive & Palliative Care

6. Baclofen

palsy. SEARCH METHODS: We searched the CENTRAL, MEDLINE, EMBASE and CINAHL databases, handsearched recent conference 2015 3. Baclofen for alcohol withdrawal. BACKGROUND: Baclofen shows potential for rapidly reducing symptoms of severe alcohol withdrawal syndrome (AWS) in people with alcoholism. Treatment with baclofen is easy to manage and rarely produces euphoria or other pleasant effects, or craving for the drug. This is an updated version of the original Cochrane Review published in 2015, Issue 4 (...) comprised of Seventy-five patients receiving baclofen and group II comprised of 75 patients receiving tolperisone. For efficacy 2017 10. A randomized, open-label, standard controlled, parallel group study of efficacy and safety of baclofen , and chlordiazepoxide in uncomplicated alcohol withdrawal syndrome. 27105601 2016 04 23 2017 04 06 2017 04 06 2320-2890 39 1 2016 Feb Biomedical journal Biomed J A randomized, open-label, standard controlled, parallel group study of efficacy and safety of baclofen

2018 Trip Latest and Greatest

7. Alcohol dependence: the risks of high-dose baclofen

of alcohol dependence Prescrire Int 2013; 22 (141): 217. Alcohol withdrawal syndrome: preventive measures. Prescrire Int 2015; 24 (166): 300-301. High-dose baclofen: withdrawal syndrome following abrupt discontinuation Prescrire Int 2014; 23 (153): 241. | | | Prescrire Your change of address has been received and will be processed promptly but will not appear instantaneously Prescrire Your message has been sent (...) Alcohol dependence: the risks of high-dose baclofen Prescrire IN ENGLISH - Spotlight ''Alcohol dependence: the risks of high-dose baclofen '', 1 November 2018 {1} {1} {1} | | > > > Alcohol dependence: the risks of high-dose baclofen Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |   |   |  Spotlight Alcohol dependence: the risks of high-dose baclofen With high-dose

2018 Prescrire

8. Baclofen in gamma-hydroxybutyrate withdrawal: patterns of use and online availability Full Text available with Trip Pro

Baclofen in gamma-hydroxybutyrate withdrawal: patterns of use and online availability Gamma-hydroxybutyrate (GHB) withdrawal is a life-threatening condition that does not always respond to standard treatment with benzodiazepines. Baclofen has potential utility as a pharmacological adjunct and anecdotal reports suggest that it is being used by drug users to self-manage GHB withdrawal symptoms. Here, we investigate current patterns of use and the online availably of baclofen.Data triangulation (...) techniques were applied to published scientific literature and publicly accessible Internet resources (grey literature) to assess the use of baclofen in GHB withdrawal. An Internet snapshot survey was performed to identify the availability of baclofen for online purchase and the compliance of retailers with the UK regulations. Data were collected according to pre-defined criteria.A total of 37 cases of baclofen use in GHB withdrawal were identified in the scientific literature, as well as 51 relevant

2017 European journal of clinical pharmacology

9. Baclofen in Managing Acute Alcohol Withdrawal

Baclofen in Managing Acute Alcohol Withdrawal Baclofen in Managing Acute Alcohol Withdrawal - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Baclofen in Managing Acute Alcohol Withdrawal The safety (...) by (Responsible Party): Universitair Ziekenhuis Brussel Study Details Study Description Go to Brief Summary: The study goal is to investigate whether administration of oral baclofen forms an adequate treatment option in the management of acute alcohol withdrawal. The investigators will compare placebo with doses of baclofen 30 and 60 milligram per day (mg/day) in a randomized controlled trial including patients receiving symptom triggered diazepam. Condition or disease Intervention/treatment Phase Alcohol Use

2017 Clinical Trials

10. Baclofen for alcohol withdrawal. (Abstract)

Baclofen for alcohol withdrawal. The treatment of baclofen can rapidly reduce symptoms of severe alcohol withdrawal syndrome (AWS) in alcoholic patients, with a significant reduction in the cost. Baclofen is easily manageable, what's more, no patient treated with baclofen reported euphoria or other pleasant effects caused by the drug and no subject reported any degree of craving for the drug.To assess the efficacy and safety of baclofen for patients with alcohol withdrawal syndrome.We searched (...) . All searches included non-English language literature.All randomised controlled clinical trials (RCTs) evaluating baclofen versus placebo or any other treatment for patients with AWS. Uncontrolled, non-randomised or quasi-randomised trials were excluded. Both parallel group and cross-over design were included.Two reviewers independently assessed references retrieved for possible inclusion. All disagreements were resolved by an independent party. Study authors were contacted for additional

2011 Cochrane

11. Baclofen Withdrawal

Baclofen Withdrawal Baclofen Withdrawal Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Baclofen Withdrawal Baclofen Withdrawal Aka (...) : Baclofen Withdrawal , Baclofen Pump , Baclofen Pump Malfunction , Baclofen Intrathecal Pump II. Background is used to reduce severe spasticity (e.g. spinal cord injury, , ) Oral poorly penetrates blood brain barrier, and requires intolerable oral doses to offer effect Instead, intrathecal has fewer side effects and may be used at low dose III. Dosing 50-100 mcg/day via (up to 900 mcg) and slowly titrate to effect Small dose modifications can have significant effects on patient findings (due to direct

2018 FP Notebook

12. Pharmacological therapies for management of opium withdrawal. Full Text available with Trip Pro

was provided for several days, we mainly focused on day 3. The reason for this was that the highest severity of opium withdrawal is in the second to fourth day.Comparing different pharmacological treatments with each other, clonidine was twice as good as methadone for completion of treatment (risk ratio (RR) 2.01, 95% confidence interval (CI) 1.69 to 2.38; 361 participants, 1 study, low-quality evidence). All the other results showed no differences between the considered drugs: baclofen versus clonidine (...) Pharmacological therapies for management of opium withdrawal. Pharmacologic therapies for management of heroin withdrawal have been studied and reviewed widely. Opium dependence is generally associated with less severe dependence and milder withdrawal symptoms than heroin. The evidence on withdrawal management of heroin might therefore not be exactly applicable for opium.To assess the effectiveness and safety of various pharmacologic therapies for the management of the acute phase of opium

2018 Cochrane

13. Baclofen Withdrawal

Baclofen Withdrawal Baclofen Withdrawal Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Baclofen Withdrawal Baclofen Withdrawal Aka (...) : Baclofen Withdrawal , Baclofen Pump , Baclofen Pump Malfunction , Baclofen Intrathecal Pump II. Background is used to reduce severe spasticity (e.g. spinal cord injury, , ) Oral poorly penetrates blood brain barrier, and requires intolerable oral doses to offer effect Instead, intrathecal has fewer side effects and may be used at low dose III. Dosing 50-100 mcg/day via (up to 900 mcg) and slowly titrate to effect Small dose modifications can have significant effects on patient findings (due to direct

2017 FP Notebook

14. A randomized, open-label, standard controlled, parallel group study of efficacy and safety of baclofen, and chlordiazepoxide in uncomplicated alcohol withdrawal syndrome. Full Text available with Trip Pro

A randomized, open-label, standard controlled, parallel group study of efficacy and safety of baclofen, and chlordiazepoxide in uncomplicated alcohol withdrawal syndrome. Alcohol withdrawal syndrome (AWS) is a distressing condition, generally controlled by benzodiazepines (BZD's). Baclofen, a gamma-aminobutyric acid-B (GABAB) agonist, has also shown promising results in controlling AWS. As there are few studies comparing the efficacy and tolerability of chlordiazepoxide with baclofen (...) , the present study was taken up. The objective of this study was to compare efficacy and tolerability of baclofen with chlordiazepoxide in uncomplicated AWS.Sixty subjects with uncomplicated AWS were randomized into two groups of 30 each, to receive baclofen (30 mg) or chlordiazepoxide (75 mg) in decremented fixed dose regime for 9 days. Clinical efficacy was assessed by Clinical Institute Withdrawal Assessment for Alcohol-Revised Scale (CIWA-Ar) and tolerability by the nature and severity of adverse

2016 Biomedical journal Controlled trial quality: uncertain

15. Oral Baclofen Withdrawal Resulting in Progressive Weakness and Sedation Requiring Intensive Care Admission Full Text available with Trip Pro

Oral Baclofen Withdrawal Resulting in Progressive Weakness and Sedation Requiring Intensive Care Admission Baclofen is a common medication used as a muscle relaxant and antispasmodic. Baclofen-withdrawal syndrome has many symptoms such as sedation, somnolence, and weakness but can include psychological symptoms. We present a 62-year-old female whose oral baclofen was not continued at a skilled nursing facility after discharge following inpatient surgery that led to the development of altered (...) mental status and respiratory insufficiency necessitating intensive care unit admission. Abrupt cessation of baclofen, no matter the mode of administration to the patient, can lead to baclofen-withdrawal syndrome.

2016 The Neurohospitalist

16. Improving GHB withdrawal with baclofen: study protocol for a feasibility study for a randomised controlled trial. Full Text available with Trip Pro

Improving GHB withdrawal with baclofen: study protocol for a feasibility study for a randomised controlled trial. GHB (gamma-hydroxybutyrate) and its pro-drugs GBL (gamma-butyrolactone) and 1,4-butanediol (1,4-BD) are central nervous system depressants whose street names include 'G' and 'liquid ecstasy'. They are used recreationally predominately for their stimulant and pro-sexual effects or for sedation to help with sleep and/or to 'come down' after using stimulant recreational drugs. Although (...) /intensive care unit. The GABAB receptor mediates most effects of GHB/GBL and the GABAB agonist, baclofen, has shown promise as an adjunct to benzodiazepines in reducing withdrawal severity when prescribed both during withdrawal and as a 2-day 'preload' prior to detoxification. The key aim of this feasibility study is provide information about recruitment and characteristics of the proposed outcome measure (symptom severity, complications including delirium and treatment escalation) to inform

2016 Trials Controlled trial quality: predicted high

17. Baclofen and severe alcohol dependence: an uncertain harm-benefit balance as of early 2013

Baclofen and severe alcohol dependence: an uncertain harm-benefit balance as of early 2013 Prescrire IN ENGLISH - Spotlight ''Baclofen and severe alcohol dependence: an uncertain harm-benefit balance as of early 2013 '', 1 September 2013 {1} {1} {1} | | > > > Baclofen and severe alcohol dependence: an uncertain harm-benefit balance as of early 2013 Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |    (...) |   |   |   |  Spotlight Baclofen and severe alcohol dependence: an uncertain harm-benefit balance as of early 2013 FEATURED REVIEW More data are needed on the efficacy and adverse effects of baclofen in alcohol dependence, compared with other options. Patients who have received thorough, well-balanced information, and decide to try baclofen as a last resort should be included in comparative clinical studies. Full review (4 pages) available for download by subscribers

2014 Prescrire

18. Continuous intrathecal baclofen (ITB) infusion for severe spasticity and dystonia

severe consequences of ITB withdrawal. Despite the large upfront cost for the procedure, the long-term effects can be potentially money saving. Final publication URL INAHTA brief and checklist INAHTA brief and checklist Indexing Status Subject indexing assigned by CRD MeSH Baclofen; Dystonia; Dystonic Disorders; Humans Language Published English Country of organisation Malaysia English summary An English language summary is available. Address for correspondence Health Technology Assessment Section (...) Continuous intrathecal baclofen (ITB) infusion for severe spasticity and dystonia Continuous intrathecal baclofen (ITB) infusion for severe spasticity and dystonia Continuous intrathecal baclofen (ITB) infusion for severe spasticity and dystonia Malaysian Health Technology Assessment (MaHTAS) Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database

2014 Health Technology Assessment (HTA) Database.

19. Blessing or burden? Long‐term maintenance, complications and clinical outcome of intrathecal baclofen pumps Full Text available with Trip Pro

baclofen pumps.We conducted a 16-year retrospective cohort study of patients with spasticity treated with an intrathecal baclofen pump at a university hospital from 2000 to 2016. The primary outcome was the rate of infection per puncture for baclofen pump refill. Secondary outcomes included the incidence of other complications, such as running out of baclofen causing symptomatic withdrawal symptoms, pump mechanical failure, pump battery end of life and the need for pump replacement. The clinical (...) Blessing or burden? Long‐term maintenance, complications and clinical outcome of intrathecal baclofen pumps The intrathecal baclofen pump is an effective treatment for spasticity. However, long-term results have reported patients' dissatisfaction and perception of disability. Potential causes include a frequent need for baclofen pump refill and risks of complications. The aim of the present study was to evaluate the long-term maintenance, complications and clinical outcome of intrathecal

2018 Surgical Practice

20. Baclofen to Prevent Relapse in Gamma-Hydroxybutyrate (GHB)-Dependent Patients: A Multicentre, Open-Label, Non-Randomized, Controlled Trial Full Text available with Trip Pro

Baclofen to Prevent Relapse in Gamma-Hydroxybutyrate (GHB)-Dependent Patients: A Multicentre, Open-Label, Non-Randomized, Controlled Trial Gamma-hydroxybutyrate (GHB) dependence is associated with a severe, potentially lethal, withdrawal syndrome and relapse rates as high as 60% within 3 months of detoxification. Baclofen has been shown to decrease self-administration of GHB in mice and reduce relapse in a case series of GHB-dependent patients. Controlled studies on the effectiveness (...) of baclofen to prevent relapse in GHB-dependent patients are lacking.The aim of this study was to assess effectiveness of baclofen in preventing relapse in GHB-dependent patients.This was an out-patient, multicentre, open-label, non-randomized, controlled trial in GHB-dependent patients (n = 107) in the Netherlands. Treatment as usual (TAU, n = 70) was compared with TAU plus baclofen 45-60 mg/day for 3 months (n = 37). Outcome measures were rates of lapse (any use) and relapse (using GHB on average once

2018 CNS drugs

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>